A novel approach to managing variation: Outpatient therapeutic monitoring of calcineurin inhibitor blood levels in liver transplant recipients

被引:38
作者
Bucuvalas, JC [1 ]
Ryckman, FC
Arya, G
Andrew, B
Lesko, A
Cole, CR
James, B
Kotagal, U
机构
[1] Childrens Hosp, Pediat Liver Care Ctr, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH 45229 USA
[2] Childrens Hosp, Div Pharm, Cincinnati, OH 45229 USA
[3] Intermt Hlth Care, Salt Lake City, UT USA
关键词
D O I
10.1016/j.jpeds.2005.01.036
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To apply the principles of statistical process control (SPC) to manage calcineurin inhibitor (CNI) blood levels. We hypothesized that the use of SPC would increase the proportion of CNI blood levels in the target range. Study design The study population consisted of 217 patients more than 3 months after liver transplantation. After demonstration of proof of concept using the rapid cycle improvement process, SPC was applied to the entire population. The change package included definition of target ranges for CNI, implementation of a web-based tool that displayed CNI blood levels on a control chart, and implementation of a protocol and a checklist for management of CNI blood levels. The principal outcome measure was the proportion of CNI blood levels in the target range. Results In the pilot study, the proportion of CNI blood levels in the target range increased from 50% to 85%. When the protocol was spread to the entire population, the proportion of drug levels in the target range increased to 77% from 50% (P < .001), whereas the range of CNI levels decreased. The rate of allograft rejection did not change. Conclusions Utilization of SPC increased the proportion of CNI blood levels in target range. These observations maybe applicable to the care of other chronic healthcare problems.
引用
收藏
页码:744 / 750
页数:7
相关论文
共 37 条
[1]   New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine [J].
Armstrong, VW ;
Oellerich, M .
CLINICAL BIOCHEMISTRY, 2001, 34 (01) :9-16
[2]  
Bachinger A, 1998, CHIRURG, V69, P957, DOI 10.1007/s001040050521
[3]  
Boggs P B, 1999, Jt Comm J Qual Improv, V25, P163
[4]   Chronic renal dysfunction late after liver transplantation [J].
Cohen, AJ ;
Stegall, MD ;
Rosen, CB ;
Wiesner, RH ;
Leung, N ;
Kremers, WK ;
Zein, NN .
LIVER TRANSPLANTATION, 2002, 8 (10) :916-921
[5]   STATISTICAL CONSIDERATIONS IN MONITORING THE SYSTOLIC HYPERTENSION IN THE ELDERLY PROGRAM (SHEP) [J].
DAVIS, BR ;
WITTES, J ;
PRESSEL, S ;
BERGE, KG ;
HAWKINS, CM ;
LAKATOS, E ;
MOYE, LA ;
PROBSTFIELD, JL .
CONTROLLED CLINICAL TRIALS, 1993, 14 (05) :350-361
[6]  
Fisher L R, 1995, Liver Transpl Surg, V1, P10, DOI 10.1002/lt.500010104
[7]   End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy - Risk of development and treatment [J].
Gonwa, TA ;
Mai, ML ;
Melton, LB ;
Hays, SR ;
Goldstein, RM ;
Levy, MF ;
Klintmalm, GB .
TRANSPLANTATION, 2001, 72 (12) :1934-1939
[8]   Cyclosporine and tacrolimus (FK506): A comparison of efficacy and safety profiles [J].
Henry, ML .
CLINICAL TRANSPLANTATION, 1999, 13 (03) :209-220
[9]   Increased tacrolimus levels during diarrhea [J].
Hochleitner, BW ;
Bösmüller, C ;
Nehoda, H ;
Frühwirt, M ;
Simma, B ;
Ellemunter, H ;
Steurer, W ;
Hochleitner, EO ;
Königsrainer, A ;
Margreiter, R .
TRANSPLANT INTERNATIONAL, 2001, 14 (04) :230-233
[10]   The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. [J].
Jain, A ;
Mazariegos, G ;
Pokharna, R ;
Parizhskaya, M ;
Kashyap, R ;
Kosmach-Park, B ;
Smith, A ;
Fung, JJ ;
Reyes, J .
TRANSPLANTATION, 2003, 75 (07) :1020-1025